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Abstract 19 
The pharmaceutical development of new chemical entities can be hampered by their 20 
solubility and/or dissolution limitations. Currently, these properties are characterised mostly 21 
during in vivo pre-clinical studies. The development of appropriate in vitro methods to study 22 
the solubility and dissolution properties in preclinical species would lead to a significant 23 
reduction or replacement of the animal experiments at this stage of development. During 24 
clinical development, media simulating the human gastrointestinal tract fluids are commonly 25 
used and a similar approach mimicking laboratory animals gastrointestinal tract fluids would 26 
impact on the preclinical stage of development. This review summarises the current 27 
knowledge regarding the gastrointestinal physiology of the most common laboratory animals, 28 
and animal simulated gastric and intestinal media are proposed. 29 
 30 
Keywords: animal, gastrointestinal physiology, biorelevant media, in vitro, dissolution 31 
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1. Introduction 34 
When reviewing the properties of new chemical entities (NCEs) emerging from industrial 35 
drug discovery pipelines, many authors have commented on the increased number of 36 
molecules which possess challenging properties for drug development (Lennernas et al., 37 
2014). Hydrophobicity and poor aqueous solubility are two properties which can compromise 38 
oral formulation development by impacting dissolution in the gastrointestinal tract and 39 
contribute to poor oral bioavailability (Stegemann et al., 2007). It is thus important to study 40 
these aspects early in the development process. 41 
The solubility and dissolution rate limitations commonly found in NCE can be categorised by 42 
the Developability Classification System (DCS) (Butler and Dressman, 2010) which 43 
subcategorises class 2 compounds (low solubility, but high permeability) to class 2a 44 
(dissolution rate limited) or class 2b (solubility limited). Knowing the class and sub-class in 45 
which a compound resides can aid the decision on formulation strategy. Solubility and 46 
dissolution rate of a compound are often determined from in vitro solubility and dissolution 47 
tests conducted during physicochemical profiling (Markopoulos et al., 2015). Media selection 48 
is of critical importance when designing the in vitro test method. Since the late 1980’s, in 49 
vitro methods have been developed with particular focus on using media that simulate human 50 
gastrointestinal fluid, known as biorelevant media, in order to improve in vitro-in vivo 51 
correlations (IVIVC), develop clinically relevant quality control methods and contribute to 52 
assessments of relative bioavailability and bioequivalence (Fotaki and Vertzoni, 2010; 53 
Gonzalez-Garcia et al., 2015; Wang et al., 2009). Over time, the complexity of these media 54 
has increased as more data have become available about gastrointestinal physiology. This is 55 
clearly illustrated by the sequential evolution of gastric and intestinal media, which have been 56 
developed by multiple groups to simulate the conditions of the human stomach and intestinal 57 
compartment in the fasted and fed states (Markopoulos et al., 2015).  58 
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Whilst the use of biorelevant media has improved the success rate of IVIVC and has 59 
contributed to formulation development strategies for clinical development projects, there 60 
remains a gap in terms of the application of a similar approach for pre-clinical formulation 61 
selection, particularly for oral toxicokinetic studies which are required to define exposure 62 
ranges for toxicology studies. The development of a pre-clinical in vitro dissolution test 63 
which could be used in combination with PBPK software to predict oral exposure at 64 
toxicologically relevant doses would facilitate a reduction in the number of preclinical in vivo 65 
studies which precede regulatory toxicology testing (McAllister, 2013). Such an approach 66 
would be in accordance with the 3Rs principle (Directive 2010/63/EU) which describes the 67 
need for the development of in vitro methods to substitute all or part of in vivo animal 68 
experimentation. Following the strategies for the development of biorelevant media to 69 
simulate gastrointestinal conditions in humans, the development of biorelevant media to 70 
simulate gastrointestinal conditions in animals could be a substantial contribution towards 71 
this goal.  72 
In order to reduce or replace in vivo preclinical absorption studies with an in vitro test, the in 73 
vitro test method conditions in terms of media and hydrodynamics should be representative 74 
of the gastrointestinal environment of commonly used laboratory animals. Historically, in 75 
vitro test methods for studying dissolution performance, were devised for the purposes of 76 
quality control and regulation of pharmaceutical products, and not always for establishing the 77 
link to the pharmacokinetic parameters of the pharmaceutical product through its in vivo drug 78 
dissolution and release. As such these compendial methods do not adequately mimic the key 79 
processes involved in the in vivo absorption process in human or in animal, which is reflected 80 
by the poor correlations often found for poorly soluble compounds (Nicolaides et al., 2001). 81 
More recently, in vitro methods have been developed to address some of the key absorption 82 
differences, such as a dynamic pH environment or the absorption step with the use of 83 
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modified compendial or artificial gastrointestinal systems (Blanquet et al., 2004; Kostewicz 84 
et al., 2014; Kostewicz et al., 2004; Tsume et al., 2015).  85 
In this review, we describe the physiological aspects of the gastrointestinal tract of dogs and 86 
rats, as the main two laboratory species used for preclinical oral absorption studies that 87 
should be considered for the development of biorelevant in vitro dissolution tests. The 88 
physiological data were reviewed alongside previously published compositions for animal 89 
biorelevant media and modifications/ new theoretical compositions are proposed to more 90 
accurately simulate the gastrointestinal fluids in both rat and dogs.  91 
 92 
2. Gastrointestinal Anatomical and Physiological characteristics of Dogs and Rats 93 
relevant to drug dissolution 94 
The impact of the physiological conditions of the gastrointestinal tract on dissolution and 95 
absorption of drugs has been discussed in detail in the literature. In summary, the pH of the 96 
fluid will influence the solubility of weak bases and acids. The presence of bile salts and 97 
phospholipids, through the formation of mixed micelles, will increase the solubility of poorly 98 
water-soluble drugs. Moreover, bile salts or phospholipids, decrease the surface tension of the 99 
medium (as amphiphilic molecules), which influences the dissolution of drugs (Fuchs and 100 
Dressman, 2014). 101 
 102 
2.1 Stomach 103 
After being chewed in the mouth and swallowed, a bolus of food is converted in the stomach 104 
to form chyme by the action of enzymatic digestion and stomach contractions from the three 105 
layers (longitudinal, circular and oblique) of smooth muscle of the stomach wall. Chyme is a 106 
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semi-liquid mixture of the gastric enzymes that are secreted in the stomach along with mucus, 107 
gastric acid, hormones and the ingested meal. The main function of the stomach is the 108 
production of chyme and its subsequent transportation into the small intestine where 109 
absorption of nutrients can take place. Minimal absorption of nutrients is found to occur from 110 
the stomach. 111 
The anatomical structure of the dog stomach is regarded to be similar to the human stomach 112 
and it is a single compartment with a fluid capacity of 0.5-1L (McConnell et al., 2008; 113 
Sjogren et al., 2014).  114 
The lumen of the rat stomach is different compared to the human stomach and it is composed 115 
of glandular and non-glandular compartments (de Zwart et al., 1999) that have a fluid 116 
capacity of 3.4mL (McConnell et al., 2008). Secretions in the rat stomach arise from the 117 
glandular portion, while the non-glandular part of the stomach is used for the storage and 118 
digestion of the food (Sjogren et al., 2014).  119 
 120 
2.1.1 Gastric Volume: The fasted state gastric fluid volume that arises from ingestion and 121 
secretion is found to be between 10 and 50 mL in dog, 0.2 mL in rat, and below 50mL in 122 
human (McConnell et al., 2008; Rathbone and McDowell, 2013; Sjogren et al., 2014) (Table 123 
1). In the fed state dog stomach, the total fluid volume is the sum of the ingested and secreted 124 
volumes. However, the secreted fluid volume is controlled by a neurohormonal response to 125 
the ingested meal and hence the total volume is quite variable. Because the rat is a continuous 126 
feeder, the secreted fluid volume is more consistent leading to total fluid volumes of about 127 
1.3mL (McConnell et al., 2008). It is interesting to note that when reporting the ratio of the 128 
water volume of the stomach to body weight, a higher ratio is found in rat (3.2g/kg body 129 
weight) than in human (2.2g/kg body weight) (McConnell et al., 2008). 130 
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 131 
2.1.2 Gastric pH: High inter-subject variability for gastric fluid pH has been reported in 132 
human studies (Bergstrom et al., 2014). High variability of gastric pH was also found in 133 
laboratory animals (Arndt et al., 2013; Kararli, 1995; McConnell et al., 2008). In the fasted 134 
state dog, a broad span of values can be found in the literature, which range from pH 1.5 to 135 
6.8. Several studies measured the pH of gastric aspirates and had reported relatively high 136 
values of pH 3 and above (Akimoto et al., 2000; Polentarutti et al., 2010; Vertzoni et al., 137 
2007). However, a fasted pH value for dog of 1.5 is generally agreed, based on values 138 
obtained through pH telemetry capsule measurements (range 0.9-2.5) (Dressman, 1986; Lui 139 
et al., 1986; Mojaverian, 1996; Sagawa et al., 2009; Youngberg et al., 1985). When using pH 140 
telemetry capsules, the high variability observed in the dog could be due to the movements of 141 
the capsule inside the stomach (due to the migrating motor complex) (Sagawa et al., 2009; 142 
Sawamoto et al., 1997). The mean pH value in the fed state is 2.1 (Dressman, 1986). Unlike 143 
humans, there is no buffering effect of food measured in the dog’s stomach after feeding, 144 
inducing less variation in the pH during postprandial phase. Moreover, the basal gastric 145 
secretion rate is lower in dogs than in humans (Dressman, 1986). The mean pH values in 146 
fasted and fed states for rats are 3.9 and 3.2 respectively (McConnell et al., 2008). In the 147 
study by McConnell et al., the authors postulate that the low content of protein in the 148 
animals’ diet may explain a higher pH in fasted than fed state, by not stimulating a food 149 
buffering effect (McConnell et al., 2008). 150 
 151 
2.1.3 Buffer Capacity: Very few data are available regarding the buffer capacity of the 152 
gastric fluids of laboratory animals. A study on fasted dogs showed a buffer capacity of 4 153 
mmol/L/∆pH (Vertzoni 2007), and 4.5 mmol/L/∆pH in fed rats (Merchant 2015), which was 154 
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significantly different from the human median value (7-18mmol/L/∆pH in fasted state, 14-155 
28mmol/L/∆pH in fed state) (Kalantzi et al., 2006a) (Table 1). 156 
 157 
2.1.4 Osmolality: The osmolality of the fasted state stomach increases from dog to human to 158 
rat with values of 74.9mOsm/kg, 171-276mOsm/kg and 290mOsm/kg, respectively (Arndt et 159 
al., 2013; Mudie et al., 2010; Pedersen et al., 2013; Pihl et al., 2008). Similarly, the fed state 160 
gastric osmolality is higher in rat than in human (794 and 217-559mOsm/kg, respectively) 161 
(Merchant et al., 2015; Mudie et al., 2010). There are no data available for the osmolality 162 
values for the fed state in dog.  163 
 164 
2.1.5 Surface tension: Similar values of surface tension are found for the fasted state in 165 
human and dog (41.9-45.7 and 33.3-43.3mN/m, respectively) (Mudie et al., 2010; Vertzoni et 166 
al., 2007). There are no data regarding the surface tension of the gastric fluids in the fasted 167 
state for the rat. In the fed state, surface tension values are close between human and rat (30-168 
31 and 38mN/m, respectively), (Merchant et al., 2015; Mudie et al., 2010; Vertzoni et al., 169 
2007). No data is available regarding the surface tension in fed state in dog. 170 
 171 
2.1.6 Enzymes: The presence of enzymes in the stomach is essential for food digestion and 172 
can impact drug dissolution and stability. In dogs and in rats, pepsin and lipase are found in 173 
the stomach and their secretion and activity is increased in the fed state (Table 1). The same 174 
holds true for pepsin in humans (Mudie et al., 2010). Regarding gastric lipase in humans, the 175 
activity decreases 1h after meal intake, before increasing again reaching a value close to the 176 
fasted state (Armand et al., 1996). 177 
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 178 
2.1.7 Gastric motility and Gastric emptying rate: Dogs have a similar gastric motility 179 
pattern to humans with a fasted (preprandial) and fed (postprandial) state pattern. The fasted 180 
state motility consists of a two hour cycle, which comprises four phases (de Zwart et al., 181 
1999; Dressman, 1986; Sjogren et al., 2014). Approximately half of the cycle duration is 182 
Phase 1, which is a quiescent phase where the stomach is mostly dormant and contractions 183 
are rare. During Phase 2, the frequency and intensity of the contractions gradually increase 184 
until reaching a maximum, which corresponds to Phase 3. This contractile activity of Phase 3 185 
allows the stomach content to migrate to the small intestine through an interdigestive 186 
migrating motility complex (IMMC). An IMMC typically lasts for 20 minutes and spreads 187 
from the proximal stomach to the ileum every 1-2h (Sjogren et al., 2014). The transition from 188 
the strong contractile activity back to the quiescent phase is Phase 4 (de Zwart et al., 1999). 189 
During the fed state, the cyclic contractile motility pattern is replaced by regular tonic 190 
contractions. These contractions mechanically digest and mix the food with the gastric 191 
secretions to form chyme, which is then pushed towards the lower part of the stomach. 192 
Contractions of the lower part of the stomach allow the liquids and fine particles to pass into 193 
the duodenum, while larger particles are sent back to the body of the stomach. The motility 194 
pattern of the fasted state resumes when the meal is completely converted to chyme and has 195 
passed into the small intestine. 196 
In both dog and human, the gastric emptying rate depends on the type of meal ingested (solid 197 
or liquid, nutrient or non-nutrient), but overall, the emptying rate is faster in dog than in 198 
human (Table 1). For non-nutrient liquids in dog, the emptying half-life is approximately four 199 
to five minutes, and for nutrient liquids values of twenty to twenty five minutes have been 200 
reported (Dressman, 1986). When compared to liquids, the emptying rate for solids in both 201 
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dog and human are considerably slower with an emptying half-life of ninety minutes for dog 202 
(Dressman, 1986).  203 
 204 
Regarding gastric motility in rat, limited data are available, however, Sjogren et al reported a 205 
fasted state gastric emptying half-life of around 15 to 30 minutes for liquids (Sjogren et al., 206 
2014). It should also be noted that rodents are continuous feeders unlike dogs or humans and 207 
hence a different motility pattern is expected. 208 
 209 
2.2 Small intestine 210 
The intestinal wall is composed of three layers: the mucosa, in contact with the chyme, the 211 
lamina propria, which contains mucosa-associated lymphoid tissue (MALT), and the 212 
muscularis, which has longitudinal and circular layers of smooth muscle. The mucosa 213 
contains several cell types, which exhibit different functions. These include goblet cells that 214 
produce mucus, endocrine cells that secrete hormones and peptides, immune cells (paneth 215 
cells) that produce protein rich material and protect the mucosa,  and enterocytes 216 
(undifferentiated cells and absorptive cells) that allow the renewal of the mucosa and 217 
transport nutrients to the blood (de Zwart et al., 1999). 218 
The small intestine is divided into three sections: the duodenum, the jejunum and the ileum. 219 
The length of the dog small intestine is strongly dependent on the breed, but is generally 220 
shorter than in human (3-5m in humans, 2.5-4.1m in dogs (Sjogren et al., 2014)) (Table 2). 221 
The rat small intestine is shorter than both human and dog with a typical length of 82cm 222 
(Clemens and Stevens, 1980). 223 
 224 
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2.2.1 Intestinal motility and Intestinal transit times: When considering transit time, the 225 
length of the intestine should be taken into account along with motility. In most species, the 226 
small intestine has two distinct motility patterns that are dependent on the prandial state. This 227 
intestinal motility mixes the chyme with bile salts and pancreatic enzymes and also moves 228 
this mixture down the digestive tract. In the fasted state, "housekeeping" contractions 229 
propagate from the stomach through the entire small intestine, pushing forward the intestinal 230 
contents (de Zwart et al., 1999). This motility typically results in a transit time through the 231 
dog small intestine of 2 hours, which is approximately half the transit time in human (Table 232 
2) (Dressman, 1986). However, when considering the relative lengths of the dog and human 233 
small intestine, the transit rates are similar in the two species (de Zwart et al., 1999). In the 234 
rat, the intestinal transit time is similar to human (3 to 4 hours), hence the transit rate in rat is 235 
much slower in comparison to human or dog (Table 2).  236 
In the fed state, the small intestine undergoes segmentation contractions and peristalsis. The 237 
segmentation contractions mix the chyme with the intestinal secretions and add mechanical 238 
sheer force to the digestion. Moreover, these contractions facilitate contact of the chyme with 239 
the gut epithelium, promoting the absorption process (de Zwart et al., 1999). The peristaltic 240 
contractions create pressure behind the volume of chyme enabling movement towards the 241 
anus (de Zwart et al., 1999).  242 
 243 
2.2.2 Surface area: A further enhancement to the intestinal absorption process is the large 244 
surface area of the gut epithelium. The presence of numerous villi and microvilli significantly 245 
increases the surface of the intestine available for absorption (54cm2/cm length jejunum, 246 
38cm2/cm length ileum for dog, 1m2 absolute surface area for rat) (Hatton et al., 2015; 247 
Rathbone and McDowell, 2013). 248 
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 249 
2.2.3 Volume: The water volumes in the human small intestine were found to be 105 mL in 250 
the fasted state and a lower volume of 54 mL in the fed state (Schiller et al., 2005). Reported 251 
volumes in the dog small intestine were not found, but are expected to be equivalent to 252 
human. However, the equivalent volumes in rat were found to be higher in the fed state than 253 
the fasted state with reported values of 1.2 mL and 3.4 mL, respectively (McConnell et al., 254 
2008). Similar to stomach volumes, the proportion of water volume in the intestine to body 255 
weight, was higher in rat than in human (11.1g/kg and 3.8g/kg respectively) (McConnell et 256 
al., 2008).  257 
 258 
2.2.4 pH: Secretions from intestinal glands and from the pancreas increases the pH of the 259 
chyme coming from the stomach. This prevents irritation of the intestinal epithelium from 260 
elevated acidity levels, and produces optimal conditions for the enzymes.  261 
A similar pattern of increase of pH values along the small intestine can be observed in 262 
humans and rats, both in fasted and fed state (human fasted: from 5.6 to 8.0, rat fasted: 5.89 263 
to 5.93, human fed: 5.0 to 8.0, rat fed: 5.0 to 5.94) (Bergstrom et al., 2014; McConnell et al., 264 
2008; Sjogren et al., 2014) (Table 2). The same is true for the dog in fasted state, with a pH 265 
increasing from 5.0 to 7.9 (Sutton, 2004) (Table 2). No values are available regarding the 266 
different pH values along the length of small intestine of the dog in fed state. 267 
The intestinal pH is consistently 1 unit higher in dog than in human when comparing 268 
measurements at times normalized to gastric emptying of the pH measuring device. The 269 
duodenal pH in the fed state in dogs is lower than the duodenal pH in the fasted state and it 270 
decreases more rapidly and to a greater extent than in humans (change of pH from pH7 to 271 
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pH3 in 90min in dogs, compared to the pH change from pH6 to pH5 in 4h in humans) 272 
(Dressman, 1986). 273 
 274 
2.2.5 Buffer capacity: The buffer capacity of the intestinal fluid in the dog is much lower 275 
than that of human, in the fasted state (Table 2). The buffer capacity was found to be 276 
1.4mmol/L/∆pH in dog, and values in human were found to vary from 3.2 to 6.4 277 
mmol/L/∆pH (Kalantzi et al., 2006a; Mudie et al., 2010). In the fed state, the buffer capacity 278 
is greater than in the fasted state, but decreases along the gastrointestinal tract in human (30 279 
to 13.2 mmol/L/∆pH) and rat (28.2 to 20.1 mmol/L/∆pH) (Table 2) (Merchant et al., 2015; 280 
Mudie et al., 2010). However, the buffer capacity throughout the fed state dog small intestine 281 
is more constant with values of 24-30mmol/L/∆pH (Kalantzi et al., 2006a). 282 
 283 
2.2.6 Osmolality: Under fasted state conditions, the osmolality of the intestinal fluids in dog 284 
was reported to be ~70 mOsm/kg. In comparison, the osmolality found for the fasted state 285 
human intestine with duodenal fluids at 124-266 mOsm/kg, and a further rise to a value of 286 
200-278mOsm/kg in the human jejunal fluids. The opposite was observed under fed state 287 
conditions, with values of 250-367 mOsm/kg in human duodenal fluid compared to the 288 
higher values of  667-841 mOsm/kg in dog intestinal fluid (Table 2) (Kalantzi et al., 2006a; 289 
Mudie et al., 2010). Osmolality values of the rat intestinal fluids in the fasted state were not 290 
found in the literature. The osmolality values of the rat intestinal fluids in the fed state were 291 
comparable to the osmolality values of the dog intestinal fluids and osmolality decreased 292 
from the proximal to the distal regions of the small intestine (896 to 546 mOsm/kg) 293 
(Merchant et al., 2015).  294 
 295 
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2.2.7 Surface tension: The reported values for the surface tension of the intestinal fluids 296 
were similar between human, dog and rat, both in the fasted and in the fed state (about 297 
30mN/m) (Table 2) (Kalantzi et al., 2006a; Merchant et al., 2015; Mudie et al., 2010). An 298 
important element in the value of the surface tension is the presence of lipids. In dogs, the 299 
concentration of neutral lipids has been measured, in the fed intestine, at 12.2mM (Persson et 300 
al., 2005). In the fasted rat, the composition of fatty acids from the bile duct is: palmitic acid 301 
(31%), vaccenic acid (20%), linoleic acid (19%) and arachidonic acid (18.5%) (Ramaprasad 302 
et al., 2006). 303 
 304 
2.2.8 Bile and phospholipids: An important element of intestine physiology, when 305 
considering drug dissolution is bile. By its properties of wetting and solubilisation, bile is a 306 
major factor in the digestion of fats and fat-soluble products. It is also involved in the 307 
elimination of many waste products into the bile and then in faeces (de Zwart et al., 1999). 308 
Bile is produced in the liver by the hepatocytes, and depending on the species, stored and 309 
concentrated in the gall bladder before being released in the intestine. Some anatomical 310 
differences have been noted between species, showing that dogs do not have a sphincter to 311 
regulate the release of bile into the intestine (de Zwart et al., 1999), and rats lack a gall 312 
bladder and present a diurnal rhythm (with highest flow at night) (Holm et al., 2013). In 313 
humans, bile is produced continuously (800mL/day), with a flow normalized to body weight 314 
of 1.5-15.4µL/min/kg (Holm et al., 2013). The bile flow is higher in rats (30-150µL/min/kg) 315 
than in dogs (13.2-25µL/min/kg) and humans (Holm et al., 2013; Rathbone and McDowell, 316 
2013). Bile is a complex fluid containing water, electrolytes and organic molecules such as 317 
bile acids (water-soluble derivatives of cholesterol), cholesterol, phospholipids and bilirubin. 318 
Bile acids can be classified into two groups, primary and secondary bile acids. Primary bile 319 
acids are synthesized de novo from cholesterol in the liver via different pathways involving 320 
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many enzymes. Secondary bile acids are formed in the large intestine and the terminal ileum 321 
after bacterial hydrolysis, dehydroxylation, epimerisation and oxidation of hydroxyl groups 322 
(Holm et al., 2013). The secondary bile salts are absorbed and recirculated by the 323 
enterohepatic circulation. The main primary bile acids in mammalian species are cholic acid 324 
and chenodeoxycholic acid (Holm et al., 2013). In human, almost all primary bile acids 325 
(98%) are conjugated with amino acids in liver peroxisomes prior to their active secretion 326 
from the liver into the gallbladder and the small intestine (Holm et al., 2013). The hepatic bile 327 
salts are mainly conjugated by glycine, whereas in the duodenum, the bile acids are 328 
conjugated in the same proportions with glycine and taurine (de Zwart et al., 1999). In dogs, 329 
the bile salts are conjugated with taurine only (Falany et al., 1994), and the most abundant 330 
bile salt is taurocholic acid (Holm et al., 2013). The major bile acids in rats are taurine 331 
conjugated (Holm et al., 2013) with taurocholic acid as the main one (Sjogren et al., 2014). β-332 
muricholic acid is also largely represented in the rodent bile (de Zwart et al., 1999). The 333 
differences in bile salt type and conjugation between dogs, rats and humans result in higher 334 
hydrophilicity values for dog and rat bile salts relative to their human counterparts (de Zwart 335 
et al., 1999; Holm et al., 2013) In the fasted state, the rat generates a higher bile salt 336 
concentration (17-61.3mM) than dog (2.4-10mM) or human (2.5-5.9mM in duodenum, 1.4-337 
5.5mM in jejunum). In the fed state, higher concentration of bile salts are found in the dog 338 
intestine (8-18mM) than in human (3.6-24mM in duodenum, 4.5-8.0mM in jejunum) (Table 339 
2) (Arndt et al., 2013; Bergstrom et al., 2014; Kalantzi et al., 2006a; Persson et al., 2005). In 340 
humans, dogs, as well as in rats the most common phospholipid in the bile is 341 
phosphatidylcholine, with a proportion of about 95% (Bergstrom et al., 2014), but the amount 342 
of phospholipids is higher in dog and rat than human (Bergstrom et al., 2014; Kalantzi et al., 343 
2006a) (Table 2). 344 
 345 
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3. Biorelevant animal simulated gastrointestinal media 346 
Human biorelevant media have been successfully applied to in vitro solubility and dissolution 347 
studies for improved bioprediction. Using a similar strategy for the development of 348 
biorelevant animal media, improved bioprediction could lead to a reduction in the use of 349 
animals in toxicology studies during the early stages of drug development. 350 
As most drugs are developed for oral delivery, the focus for this study was to develop new 351 
simulated media for the stomach and small intestine fluids under fasted and fed state 352 
conditions, for both the dog and the rat. The development of the new media was based on 353 
existing published recipes. The main properties considered were: pH, osmolality, buffer 354 
capacity, surface tension, as well as composition and concentration of bile salts, 355 
phospholipids, fatty acids, ions, salts and enzymes.  356 
Bile salts, phospholipids and fatty acids should be carefully selected to reflect the 357 
physiological components of gastrointestinal fluids and control surface tension. For example, 358 
lysophosphatidylcholine and the fatty acids; sodium oleate, glyceryl monooleate and palmitic 359 
acid are used to simulate the physiological enzyme degradation products (Arndt et al., 2013). 360 
With respect to bile salts, the use of pure bile salts is preferred to bile salt extracts in order to 361 
overcome issues of reproducibility related to variable composition between batches (Vertzoni 362 
et al., 2004). Concerning the type of bile salts, taurocholates are preferred as it has been noted 363 
that micelles from trihydroxy acids are relatively insensitive to changes in pH, ionic strength 364 
and temperature (Vertzoni et al., 2004). Bicarbonate salts are also found in the 365 
gastrointestinal tract, which are pH buffer components, but the technical difficulties related to 366 
their use has led to a preference for phosphate buffers in many simulated biological media 367 
(Sheng et al., 2009). The technical difficulties arise from a low stability of H2CO3, which 368 
decomposes at biological pH to form the poorly soluble gas CO2. In order to retain the buffer 369 
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component HCO3
- in the system CO2 is sparged into the medium (Sheng et al., 2009), which 370 
causes a change to the pH. Therefore the stability of the pH is dependent on the rate at which 371 
CO2 is sparged and is often found to be less stable than a phosphate buffer system. 372 
Furthermore, the subsequent formation of bubbles in the dissolution medium can cause 373 
mechanical stress and high variability in dissolution profiles (Boni et al., 2007). Even though 374 
commercially available setups make the use of bicarbonate buffers easier, it has been 375 
demonstrated that the use of non-physiologically relevant anions (such as phosphates) instead 376 
of bicarbonates in media will not impact on the dissolution of weak bases which have a pKa 377 
below 5, but will influence the dissolution of highly lipophilic compounds with extremely 378 
low solubility (Vertzoni et al., 2004).  379 
 380 
In this paper, we present published media recipes and discuss possible modifications. Further, 381 
we propose the theoretical composition of new media based on the available physiological 382 
data in order to simulate both the stomach and the small intestinal fluids of the dog and the rat 383 
in the fasted and fed state. 384 
 385 
3.1 Canine fasted state simulated gastric fluid (cFaSSGF) 386 
Modification of a medium already published in the literature is suggested based on the 387 
physiological values. A dog stomach simulated medium has been developed by Arndt and 388 
coworkers in 2013 (Arndt et al., 2013). A pH value of 1.5 (Table 3) reflects the strong acidity 389 
of the dog stomach (Dressman, 1986) and is prepared using concentrated hydrochloric acid 390 
(37%). Sodium chloride is used in the medium in order to achieve the desired osmolality. 391 
Whilst bile salts, phospholipids and fatty acids are not produced in the stomach, they are 392 
often found to be present in a fasted gastric medium through a reflux mechanism from the 393 
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duodenum (Arndt et al., 2013). To represent bile reflux, a concentration of 0.2 mM of bile 394 
salt and 0.05 mM of phospholipid was added to the simulated gastric medium. These 395 
concentrations also maintain the 4:1 ratio of bile salts to phospholipids recorded in the canine 396 
intestinal fluid in the fasted state (Arndt et al., 2013).  397 
It is proposed to modify the medium proposed by Arndt et al. to include the addition of 398 
enzymes in the medium. Based on the pepsin and lipase levels measured in the dog stomach 399 
(Table 1) in the studies of Magee and Naruse (1983) and Carriere et al., (1992), the addition 400 
of pepsin (600U/h,) and lipase (190U/h) to the medium is suggested (Table 3)(Carriere et al., 401 
1992; Magee and Naruse, 1983). It is important to note that the optimal pH for pepsin activity 402 
is 2.0, and that gastric lipase is inactivated below pH 1.5 (Smeets-Peeters et al., 1998). 403 
Therefore pH should be carefully maintained in order to keep the enzymatic activity of the 404 
lipase, in the case that the enzyme is included in the medium when digestion of lipid based 405 
formulations is an important factor to be assessed. 406 
 407 
3.2 Canine fed state simulated gastric fluid (cFeSSGF) 408 
A medium simulating the dogs’ stomach in the fed state has not been described in the 409 
literature. This medium would be highly dependent on the ingested meal. A medium 410 
representing the meal given to the animals or a milk-based medium could be used to simulate 411 
this physiological condition. The simulated media of the human gastric fluids in the fed state 412 
(FeSSGF) or long-life milk could be a good substitute for the dog’s stomach fluids in the fed 413 
state (Dressman et al., 1998; Markopoulos et al., 2015). As the pH of these media is much 414 
higher than the pH of the dog’s fed stomach the pH should be reduced at time 0, i.e. with the 415 
addition of an acidic solution of pepsin. 416 
 417 
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3.3 Canine fasted state simulated intestinal fluid (cFaSSIF) 418 
A medium representing canine fasted state simulated intestinal fluid was published (Arndt et 419 
al., 2013). Here, taurocholic acid and taurodeoxycholic acid were found to be the most 420 
abundant tauro-conjugated bile acids at a concentration of 10mM in fasted state canine 421 
intestinal fluid (Arndt et al., 2013; Falany et al., 1994; Holm et al., 2013). Hence, the bile salt 422 
sodium taurocholate and sodium taurodeoxycholate were prepared to a concentration of 5mM 423 
each (10mM total) (Table 3). Based on this bile salt concentration, and the 4:1 ratio between 424 
bile salts and phospholipids, the phospholipid concentration of the medium was 2.5mM, 425 
using equimolar concentrations of phosphatidylcholine and lysophosphatidylcholine (Table 426 
3). Sodium oleate was included as a product of lipolytic activity, in equimolar concentration 427 
to lysophosphatidylcholine (Arndt et al., 2013). The combination of the two bile salts with 428 
the use of lysophosphatidylcholine and sodium oleate results in the desired surface tension of 429 
41.9-45.7 mN/m measured in the dogs intestinal fluids in the fasted state (Arndt et al., 2013). 430 
Sodium phosphate buffer, sodium hydroxide and sodium chloride were used to control the 431 
desired osmolality and buffer capacity at pH 7.5.  432 
In order to take into account the variability and reflect the distribution of dog intestinal pH 433 
values reported in the literature a modification from pH 7.5 to pH 6.8 (median pH value in 434 
fasted intestinal canine lumen) is proposed (Table 2), with a possible impact on solubility of 435 
weak acids. The values for all the other components and properties of the medium published 436 
by Arndt et al. (2013) are physiologically relevant. 437 
 438 
3.4 Canine fed state simulated intestinal fluid (cFeSSIF) 439 
A medium simulating the dog intestine in the fed state has not been described in the literature 440 
and a novel medium is proposed based on reported values of the characteristics of the dog 441 
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intestinal contents in the fed state. The pH of this medium is set at 6.3, as this was the median 442 
value reported in the literature, and a phosphate buffer or maleate buffer is suggested (Diem, 443 
1962). In an article by Persson and coworkers, an extract of the dog intestinal contents in the 444 
fed state was found to have a bile salt concentration of 5 mM. As in the dog intestinal fluids 445 
in the fasted state, the main two bile acids were found to be taurocholic acid (74%) and 446 
taurodeoxycholic acid (21%) (Persson et al., 2005). But, the relative percentage had changed 447 
from 50% of both bile salts in the fasted state to 74% sodium taurocholate and 21% sodium 448 
taurodeoxycholate in the fed state. For simplicity, 75% and 25% were used, leading to 449 
concentrations of 3.75 and 1.25 mM, respectively to account for the total 5mM bile salt 450 
concentration found. A bile salt:phospholipid ratio of 4:1 was reported, indicating a 1.25 mM 451 
phospholipid concentration in the dog intestinal fluids in the fed state, with the 452 
lysophosphatidylcholine and phosphatidylcholine being the main ones (Persson et al., 2005). 453 
However, a lower bile salt:phospholipid ratio of 1:1 was reported by Kalantzi et al (Kalantzi 454 
et al., 2006b). Hence, an average bile salt:phospholipid ratio of 2.5:1 was selected 455 
(5mM:2mM). Fatty acids at a concentration of 12.2 mM were measured in the dog intestinal 456 
fluid in the fed state (Persson et al., 2005). As a suitable fatty acid was not specified in the 457 
literature for the dog intestinal fluid glyceryl monooleate was selected, as this fatty acid has 458 
been suggested in the fed state human simulated intestinal fluid, (FeSSIF-V2, (Jantratid et al., 459 
2008) (Table 3). 460 
 461 
3.5 Rat fasted state simulated gastric fluid (rFaSSGF) 462 
A medium simulating the rat stomach in the fasted state has not been described in the 463 
literature and a novel medium is proposed based on reported values of the characteristics of 464 
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the rat gastric contents in the fasted state. The pH is set at 3.9, which was based on the 465 
physiological value determined by McConnell et al (McConnell et al., 2008) (Table 4).  466 
Bile reflux is known to occur in the rat and hence a bile salt concentration of 4mM is 467 
suggested based on the physiological values (Tanaka et al., 2014). Sodium taurodeoxycholate 468 
was not found to be in significant quantities in the rat bile duct, therefore only sodium 469 
taurocholate was selected (Alvaro et al., 1986). The bile salt:phospholipid ratio was found to 470 
be significantly greater in rat than in dog with reported values of 23:1 (Tanaka et al., 2012). 471 
As such a 0.2 mM concentration of phospholipid is proposed. Only trace quantities of 472 
lysophosphatidylcholine were detected in rat gastric fluid, therefore only phosphatidylcholine 473 
is the proposed phospholipid for this medium (Alvaro et al., 1986). Regarding enzymes, in 474 
fasted state, the secretion of pepsin in the rat stomach is 1.2µg/h (Shahroki et al., 2015), 475 
(Table 4). Lipase activity has been measured at 44.3U/h (Levy et al., 1981) (Table 4). 476 
 477 
3.6 Rat fed state simulated gastric fluid (rFeSSGF) 478 
A medium simulating the rat stomach in the fed state has not been described in the literature. 479 
A medium representing the meal given to the animals, or a buffer of pH 3.2 (reflecting the 480 
physiological pH value of the rat stomach) with the addition of sodium taurocholate, 481 
phosphatidylcholine and fatty acids, which have been identified (but not quantified) in the rat 482 
stomach fluids in the fed state, are suggested. To the best of our knowledge, no data are 483 
available regarding the concentrations of these components in the rat stomach fluids in the 484 
fed state. 485 
 486 
3.7 Rat fasted state simulated intestinal fluid (rFaSSIF) 487 
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Modification of a medium already published in the literature is suggested based on the 488 
physiological values. A medium to simulate the rats’ intestinal fluid in the fasted state has 489 
been proposed by Tanaka et al. (2014). The first modification proposed refers to the pH of the 490 
medium. Based on the median value of the pH of the rats intestinal fluids in the fasted state 491 
(Table 2) a modification from pH 7.0 (value based on measurements at 10-15 min intervals 492 
over 75 min after administration of 1mL ultrapure water) (Tanaka et al., 2014) to pH 6.0 is 493 
proposed. 0.2 M sodium dihydrogen phosphate, 0.2 M acetic acid and 0.2 M sodium 494 
hydroxide are suggested as the buffer system for the desired pH value (pH 6.0). A 495 
concentration of 50mM of sodium taurocholate is used in the published medium, that is based 496 
on the measured concentration of bile acids in the upper jejunum (Tanaka et al., 2012) and 497 
taurocholic acid was found to be the main bile acid in the rat intestine (Sjogren et al., 2014). 498 
The second modification proposed refers to the phospholipid concentration in the medium. In 499 
the published medium a 3.7mM egg phosphatidylcholine is suggested as the phospholipid for 500 
the medium. Based on the physiological value for the bile salt:phospholipid concentration 501 
ratio of 23:1 we suggest the addition of 2.2 mM phosphatidylcholine in the medium (Tanaka 502 
et al., 2012) (Table 4).  503 
 504 
3.8 Rat fed state simulated intestinal fluid (rFeSSIF) 505 
A medium simulating the rat intestine in the fed state has not been described in the literature 506 
and a novel medium is proposed based on reported values of the characteristics of the rat 507 
intestinal contents in the fed state. The pH is set at 5.5, as the physiological pH values range 508 
from a value of 5.0 for the duodenum to a value of 5.94 for the ileum, as stated in McConnell 509 
et al.(McConnell et al., 2008) (Table 2). Sodium taurocholate and phosphatidylcholine are 510 
suggested in order to represent the main bile salts and phospholipids and are set at 511 
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concentrations of 13.7 mM and 6.3 mM, respectively (Table 4). With respect to fatty acids, 512 
palmitic acid is proposed as the representative fatty acid as it was found to be the main 513 
component (31%) measured in the bile duct of fed rats (Ramaprasad et al., 2006) [in terms of 514 
simplification of the medium the addition of one fatty acid is proposed]. As there are no 515 
information available regarding the fatty acids’ concentration, a concentration of 18.3mM is 516 
proposed, based on the monoglycerides-fatty acids/phospholipids ratio (2.9:1) that is used in 517 
the human fed state simulated intestinal fluid (FeSSIF-V2) (Jantratid et al., 2008).  518 
 519 
4. Conclusions 520 
In the last decades, several media simulating the human gastrointestinal tract have been 521 
developed and successfully used. However, limited information is available for media to 522 
simulate the gastrointestinal tract of laboratory animals. This review summarises the limited 523 
available media mimicking dogs and rats digestive tract, suggesting modifications, and 524 
proposes novel ones based on the most recent physiological data available. The use of these 525 
media would support the 3Rs as well as it would be used as a tool to develop in vitro in vivo 526 
correlations. Further studies which will assess the potential of using these newly developed 527 
media with a novel mini-scale dissolution method to improve the prediction of oral 528 
formulation performance in preclinical species are in progress. 529 
 530 
 531 
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Tables 726 
Table 1: Comparative Anatomical and Physiological characteristics of the Stomach in 727 
humans, dogs and rats 728 
 Human Dog Rat 
Gastric emptying time t1/2 liquids: 8-15 
min a 
t1/2 meal: 30min-
3h b 
t1/2 liquids: 4-5 
min a 
t1/2 meal: 90min a 
 
 
t1/2 meal: 15–30 
min b 
Water volume <50mL (fasted) b 
Up to 1L (fed) b 
Similar to humans 
especially for dogs 
>20kg b 
0.2mL (fasted) c 
1.3mL (fed) c 
pH Fasted 1.7-3.3 d 1.5±0.04 a 3.9 c 
Fed 3.5 e 2.1 a 3.2 c 
Osmolality 
(mOsm/kg) 
Fasted 171-276 f,g 74.9±6.0 h 290 i 
Fed 217-559 f  794±260 j 
Surface tension Fasted 41.9-45.7 f 37.3 (33.3-43.3) k  
Fed 30-31 f  38±2 j  
Buffer capacity 
(mmol/L/∆pH) 
Fasted 7-18 l 4.0 (0.6-6.6) k  
Fed 14-28 l  4.5±1.9 j 
Enzymes Pepsin 81mg/h v, 0.1-
1.3mg/mL (fasted) 
f,  
273-339 mg/h v,  
0.26-1.72 mg/mL 
600U/h (fasted) q 
1.56±0.60mg/h for 
the first hour and 
0.56±0.15mg/h for 
the second hour 
12µg/mL, 1.2µg/h 
(fasted) s, u 
31 
 
(fed) f (fed) r 
Lipase ≈ 43.9 U/mL o, 
0.1mg/mL (fasted) 
m 
11.4-43.9U/mL 
(fed) o 
190U/h (basal 
secretion) n, 
7.2mg over 3h 
digestion (fed) p 
44.3U/h/g wet 
tissue t 
a)(Dressman, 1986), b)(Sjogren et al., 2014), c)(McConnell et al., 2008), 729 
d)(Bergstrom et al., 2014), e)(de Zwart et al., 1999), f)(Mudie et al., 2010), 730 
g)(Pedersen et al., 2013), h)(Arndt et al., 2013), i)(Pihl et al., 2008), j)(Merchant et 731 
al., 2015), k)(Vertzoni et al., 2007), l)(Kalantzi et al., 2006a), m) (Carriere et al., 732 
2000), n)(Carriere et al., 1992), o) (Armand et al., 1996), p) (Carriere et al., 1993), 733 
q)(Magee and Naruse, 1983), r) (Kondo et al., 1994), s)(Asokkumar et al., 2014), 734 
t)(Levy et al., 1981), u) (Shahroki et al., 2015), v) (Lentner, 1981) 735 
 736 
  737 
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 738 
Table 2: Comparative Anatomical and Physiological characteristics of the Small 739 
Intestine in humans, dogs and rats 740 
 Human Dog Rat 
Length 3-5m a  2.5-4.1m a  0.82m  b  
Absorbing surface 200m2 c  54cm2/cm length 
jejunum, 38cm2/cm 
length ileum d 
1m2 e 
Small intestine transit 
time 
4h (fasted or light 
meal) f   
2h (fasted) f 3-4h (fasted) a  
Water volume Fasted 105mL g   1.2mg h 
Fed 54mL g  3.4mL h 
pH Fasted 5.6-7.0 (duodenum); 
6.0-7.8 (jejunum); 
6.5-8.0 (ileum) 
 a, i 
5.0-7.6 
(duodenum), 6.2-
7.3 (jejunum), 6.6-
7.9 (ileum) j 
 
5.89 
(duodenum), 
6.13 (jejunum), 
5.93 (ileum) 
h 
Fed 5.0-6.5 (duodenum); 
5.0-6.5 (jejunum); 
similar to fasted 
(ileum) a, i 
5.0 (duodenum) j 5.0 (duodenum), 
5.10 (jejunum), 
5.94 (ileum) h 
Osmolality 
(mOsm/kg) 
Fasted 124-266 (duodenum), 
200-278 (jejunum) k 
~70 l  
Fed 250-367 (duodenum) 667-841 l 896±104 
33 
 
k (proximal), 
640±73 (mild), 
546±62 (distal) 
m 
Buffer 
capacity 
(mmol/L/∆pH) 
Fasted 5.6 (duodenum), 3.2 
(jejunum), 6.4 
(ileum) k 
~1.4 l  
Fed 18-30 (duodenum), 
13.2-14.6 (jejunum) 
k 
24-30 l 28.2±0.8 
(proximal), 
22.7±2.4 (mild), 
20.1±0.7 (distal) 
m 
Surface 
tension 
(mN/m) 
Fasted 33.3-46.0 
(duodenum), 28 
(jejunum) k 
~31 l  
Fed 32.2-36.7 
(duodenum), 27 
(jejunum) k 
~28 l 33±1 
(proximal), 
35±1 (mild), 
39±5 (distal) m 
Bile salts Fasted 2.5-5.9mM 
(duodenum), 1.4-
5.5mM (jejununm) i 
2.4-10mM l, n 17-61.3mM i 
Fed 3.6-24.0mM 
(duodenum), 4.5-
8.0mM (jejunum) i 
8-18mM l, o 12.2-15.1mM p 
34 
 
 Phospholipids  Fasted 0.26mM 
(duodenum), 
0.19mM (Jejunum) i 
Low l 6.2-6.5mM i 
Fed 1.2-6.0mM 
(duodenum), 2.0-
3.0mM (jejunum) i 
4.36-19.4mM l  
a) (Sjogren et al., 2014), b) (Clemens and Stevens, 1980), c) (DeSesso and Jacobson, 741 
2001), d) (Rathbone and McDowell, 2013), e) (Hatton et al., 2015), f) (Dressman, 742 
1986), g) (Schiller et al., 2005), h) (McConnell et al., 2008), i) (Bergstrom et al., 743 
2014), j) (Sutton, 2004), k) (Mudie et al., 2010), l) (Kalantzi et al., 2006b), m) 744 
(Merchant et al., 2015), n) (Arndt et al., 2013), o) (Persson et al., 2005), p) (Hagio et 745 
al., 2009) 746 
 747 
  748 
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Table 3: Composition and Physicochemical properties of the Canine Simulated Media 749 
 cFaSSGF cFaSSIF cFeSSIF 
pH 1.5 6.8 ~6.3 
Bile salts Sodium 
taurodeoxycholate 
(0.1mM), sodium 
taurocholate (0.1mM) 
Sodium taurocholate 
(5.00mM), sodium 
taurodeoxycholate 
(5.00mM) 
5mM 
(3.75mM taurocholic 
acid; 1.25mM 
taurodeoxycholic 
acid) 
Phospholipids Phosphatidylcholine 
(0.025mM), 
lysophosphatidylcholine 
(0.025mM) 
Phosphatidylcholine 
(1.25mM), 
lysophosphatidylcholine 
(1.25mM) 
2mM 
phosphatidylcholine 
Fatty acids Sodium oleate 
(0.025mM) 
Sodium oleate 
(1.25mM) 
12mM Glyceryl 
monooleate 
Buffer, 
Cations, salts 
Hydrochloric acid, 
sodium chloride 
(14.5mM) 
Sodium dihydrogen 
phosphate monohydrate 
(28.65mM), sodium 
hydroxide (28mM), 
sodium chloride 
(59.63mM) 
0.07M 
monopotassium 
phosphate;0.07M 
disodium phosphate 
or 0.2M Tris acid 
maleate; 0.2N NaOH  
Enzymes pepsin (600U/h), 
lipase (190U/h) 
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 751 
Table 4: Composition and Physicochemical properties of the Rat Simulated Media 752 
 rFaSSGF rFaSSIF rFeSSIF 
pH 3.9 6.0 5.0-5.5 
Bile salts 4mM taurocholic acid 50mM Taurocholic acid 13.7mM taurocholic 
acid 
Phospholipids 0.2mM 
phosphatidylcholine 
2.2mM 
phosphatidylcholine 
6.3mM 
phosphatidylcholine 
Fatty acids   18.3mM palmitic acid 
Buffer, 
Cations, salts 
0.1M acetic acid; 
0.1M sodium 
dihydrogen phosphate 
0.02M acetic acid; 
0.02M sodium 
dihydrogen phosphate, 
0.02M sodium 
hydroxide 
 
Enzymes Pepsin (1.2µg/h), 
lipase (activity 
44.3U/h) 
  
 753 
 754 
